



Lucid Diagnostics Inc.

Q2 about inline as tests continue to ramp up. Expected high growth in 2022/23 should drive stock much higher. Lowering P/T to \$12.

Q2 about inline: Lucid recently (on August 15) reported its Q2 2022 (ending June) results. Revenue was \$0 million, compared with our and consensus estimates of \$0.2 – 0.6 million. Pro forma net loss was \$10.1 million or EPS of \$(0.28), compared with our and consensus estimates of \$(0.26) - (0.33). Lucid is still early in its commercialization so it generates minimal revenue currently, but revenue is expected to grow significantly in 2022.

EsoGuard growth: The company processed 850 EsoGuard tests in Q2, up from 533 in Q1, 303 in Q4 2021, 203 in Q3 2021, and 202 in Q2 2021. Because it is still early in the process, the company has deferred revenue recognition until cash is collected so revenue is not recorded when the tests are performed (for now).

Operating expenses: Operating expenses were \$15 million, up from \$12 million in Q1 2022 as it ramps up Lucid commercial operations.

No guidance: Management has not provided forward guidance.

Lowering 2022 estimates: We are lowering our 2022 estimates for revenues to \$4.2 million, from \$5.6 million, and for EPS to \$(1.10) from \$(0.93).

EsoGuard: EsoGuard is a molecular diagnostic esophageal DNA test shown in a published human study to be highly accurate at detecting Barrett’s Esophagus (BE), as well as EAC. The estimated addressable domestic market opportunity for EsoGuard is ~\$2 billion based on tens of millions of U.S. patients with gastroesophageal reflux disease (GERD), more commonly called acid reflux or chronic heartburn, who are BE screening candidates.

GI associations support EsoGuard: Two of the leading gastroenterology (GI) specialty associations now support Lucid’s EsoCheck Cell Collection Device and EsoGuard Esophageal DNA Test as an acceptable alternative to endoscopy.

EsoCheck: EsoCheck is a non-invasive cell collection device designed to sample cells from a targeted region of the esophagus in a five-minute office-based procedure, without the need for endoscopy. EsoCheck is meant to be used for testing with its EsoGuard tests.

Ramp in commercialization can be catalyst: Lucid plans to advance commercialization of its 2 main products (EsoGuard and EsoCheck) as well as gain additional regulatory approvals (expand usage and insurance and government coverage in the U.S. and to expand into international markets). We believe achieving key milestones and ramp in revenues will likely be catalysts for the stock.

Strong rollout: Lucid is launching a major commercial initiative to accelerate EsoGuard commercialization by targeting multiple sales and marketing channels and building Lucid’s own network of EsoCheck Test Centers to assure sufficient testing capacity and geographic coverage. The Test Center program has quickly expanded to locations in Phoenix, Denver, Salt Lake City, Las Vegas, Seattle, Portland, and Boise. Lucid is now launching an accelerated expansion into larger states across the U.S. and plans to open test centers in nine additional states this year.

Large market potential: Cancer is the 2nd leading cause of death in the U.S. (behind heart disease) with ~600,000 deaths a year. The incidence of EAC, the most common cancer of the esophagus, has quadrupled over the past 30 years.

Steady balance sheet: Lucid has \$33 million in cash and no debt so its balance sheet is steady. In October 2021, Lucid had its IPO and sold 5.0 million shares at \$14/share, raising ~\$70 million.

Positive risks versus rewards: Lucid’s devices still have long commercialization challenges ahead, but we believe the ~billion dollars market potential presents high rewards for the risks.

Current valuation attractive: We are maintaining our BUY rating, but lowering our 12-month price target to \$12 from \$13 based on a NPV analysis. This represents significant upside from the current share price and we believe this valuation appropriately balances out the company’s high risks with large upside opportunities.

Company Description

Based in New York, NY, Lucid Diagnostics is a commercial-stage medical diagnostics company focused on patients at risk of developing esophageal cancer.

United States
Healthcare

September 14, 2022

Edward Woo, CFA
(561) 327-9435
ewoo@ascendant.com

COMPANY UPDATE

Rating: BUY

Ticker: LUCD

Price: \$2.07

Target: \$12.00
(from \$13.00)

Stock Data

Exchange:	NasdaqGM
52-week Range:	\$1.69 – 13.52
Shares Outstanding (million):	39
Market cap (\$million):	\$81
EV (\$million):	\$48
Debt (\$million):	\$0
Cash (\$million):	\$33
Avg. Daily Trading Vol. (\$million):	\$0.4
Float (million shares):	9
Short Interest (million shares):	0.2
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	2022E (Cur.)	2022E (Old)	2023E (Cur.)	2023E (Old)
Q1 Mar	0.2A		4.0E	
Q2 Jun	0.0A	0.2E	4.2E	
Q3 Sep	0.4E	1.0E	4.4E	
Q4 Dec	3.6E	4.2E	5.4E	
Total	4.2E	5.6E	18.0E	
EV/Revs	11x		3x	

Earnings per Share (pro forma)

	2022E (Cur.)	2022E (Old)	2023E (Cur.)	2023E (Old)
Q1 Mar	(0.23)A		(0.23)E	(0.17)E
Q2 Jun	(0.28)A	(0.26)E	(0.22)E	(0.16)E
Q3 Sep	(0.32)E	(0.24)E	(0.21)E	(0.16)E
Q4 Dec	(0.26)E	(0.19)E	(0.19)E	(0.16)E
Total	(1.10)E	(0.93)E	(0.85)E	(0.65)E
P/E	N/A		N/A	

Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 14.

Exhibit 1: PAVmed Company Overview



Lucid is a Major Subsidiary of PAVmed Inc.



Nasdaq: PAVM

A Highly Differentiated Multi-Product Commercial-Stage Medical Technology Company



Founded 2014



Nasdaq IPO 2016



Diversified Product Portfolio



Groundbreaking Technologies Addressing Important Unmet Clinical Needs




Business Model Focused on Speed to Market

8



Nasdaq: PAVM

Innovation & Value Creation Engine



Source: Company reports

Exhibit 2: PAVmed’s Major Subsidiaries



Major Subsidiaries

Diagnostics

Lucid
diagnostics
**Early Detection of Esophageal
Precancer & Cancer**

- Commercial-stage
- Founded May 2018
- Licensed technologies from Case Western Reserve University
- Managed and financed by PAVmed
- PAVmed Stake = 75.5%
- IPO Oct 14, 2021 (Nasdaq: LUCD)

Digital Health

VERIS
HEALTH
**Digital Cancer Care Platform &
Intelligent Vascular Port**

- Founded May 2021 with acquisition of Oncodisc, Inc. and its digital health technologies
- Managed and financed by PAVmed
- PAVmed stake = 80%
- Accepted into Microsoft for Startups
- PAVmed Stake = 80%
- Target commercialization H2-2022

Source: Company reports.

Exhibit 3: Lucid Diagnostics Overview (as of October 2021)



Commercial-Stage Cancer Prevention Medical Diagnostics Company

- Founded May 2018 to license technologies underlying EsoGuard & EsoCheck from Case Western Reserve University
- ~\$25B total addressable market opportunity
- PAVmed paid ~\$50K cash, retained 82% equity
- Managed and financed by PAVmed
- ~\$30M invested over ~3.5 years
- Advanced EsoGuard & EsoCheck to commercialization
- Secured \$1,938 Medicare payment
- Nasdaq IPO October 14, 2021
- Raised \$70M in growth capital at \$467M IPO valuation
- PAVmed Stake pre-IPO 72.7%, post-IPO 75.5%




Source: Company reports.

Exhibit 4: Lucid Diagnostics



**Commercial-Stage Diagnostic Technology
Company Focused on Early Precancer Detection**



MISSION: Prevent EAC Deaths in At-Risk GERD Patients



EsoGuard
esophageal DNA test



EsoCheck
cell collection device



First and only commercially available test capable of serving as a widespread screening tool to prevent EAC deaths through early detection of esophageal precancer

Highlights



EsoGuard commercialized as LDT at dedicated CLIA/CAP Laboratory



Lucid Test Centers operating in 13 states



Effective CMS \$1938 Payment



FDA Breakthrough Device Designation



Minimum 13 Million U.S. target population already recommended for screening



EsoGuard & EsoCheck supported by professional society guidelines



Near-Term Value Inflection Milestones



Multi-Billion U.S. TAM

Source: Company reports.


Exhibit 5: EsoCheck and EsoGuard Market Opportunity

EAC Precancer Screening to Prevent EAC


Major unmet clinical need

Necessary to prevent EAC deaths through early precancer detection

~13 million high-risk GERD patients already recommended for precancer screening by professional society guidelines




EsoGuard Commercial Opportunity



Source: Company reports.


Exhibit 6: The EsoCheck Procedure

The EsoCheck Esophageal Cell Sampling Procedure



Less than 5-minute, non-invasive office-based alternative to endoscopy
 Anatomically targeted cell sampling from lower 5 cm of esophagus where BE-EAC occurs
 Protects sampled cells from dilution and contamination during device removal which is critical to accurately detect low-level precancer signal


EsoCheck Procedure Steps





Source: Company reports.

Exhibit 7: Lucid Growth Strategy

Multichannel Commercial Strategy



EsoGuard Sales Channels


		 PCP-LTC	 SPEC-INST
ESOCHECK PROCEDURE	<i>Locale</i>	Lucid Test Center (LTC)	Practice/Institution
	<i>Operator</i>	LTC NP	Nurse/NP/PA
GOAL		Order EsoGuard Test	Build EsoGuard Program
CORE MESSAGE		<ul style="list-style-type: none"> Identify Precancer in at-risk GERD patients to prevent Esophageal Cancer 	<ul style="list-style-type: none"> Drive referrals to practice or institution generating long-term patients with BE Downstream revenue opportunities (EGD, ablation, imaging, pH/manometry, surgery)

Source: Company reports.


Exhibit 8: Lucid Test Centers

Lucid Test Centers

Stage 1	Stage 2	
Glendale, AZ	Lake Forest, CA	Launched
Tempe, AZ	Columbus, OH	Launched
Scottsdale, AZ	Las Colinas, TX	Launched
Lone Tree, CO	Delray Beach, FL	Launched
Henderson, NV	TBD	3Q22
Murray, UT	TBD	3Q22
Seattle, WA	TBD	4Q22
Portland, OR	TBD	4Q22
Boise, ID	TBD	4Q22



Lucid Test Centers



EsoGuard[®]
esophageal DNA test



A new test for early detection of precursors of esophageal cancer

While reflux is common, your patients may not know that chronic GERD can lead to BE and EAC. The EsoGuard esophageal DNA test detects the cellular changes caused by reflux.

How it works: distal esophageal cells are sampled using a simple, non-endoscopic five-minute office-based procedure, shipped in the provided preservative and mailer, and analyzed at our lab. Binary results (positive or negative) are available within a few weeks.

Who should be considered for testing?

2016 American College of Gastroenterology Guidelines recommends screening in high-risk GERD patients:

Individuals >50 years old with chronic GERD (>5 years) and/or **frequent (weekly or more) GERD symptoms**

- plus two additional risk factors:
- Caucasian
 - Male
 - Central Obesity
 - Past or Present History of Smoking
 - Family History of BE or EAC

Patients may be referred to Lucid Test Centers:

9700 N 81st St, suite A-115
Scottsdale, AZ 85258

4494 W Peoria Ave Ste 115A
Glendale, AZ 85302

1845 E Broadway Rd Ste 116
Tempe, AZ 85282

For prescribing information call:
(623) 687-2386

>90%
sensitivity & specificity
in detecting Barrett's esophagus,
with and without dysplasia, as well as
esophageal adenocarcinoma!

Estimated Quarterly Operating Costs	Nurse Practitioner	\$30,000
	Medical Assistant	\$12,500
	Lease, Other	\$2,500
	Total	\$45,000
Procedure	Max tests per day	20
	Billed rate per test	\$2,000
Revenue Opportunity	Daily	\$40,000
	Weekly	\$200,000
	Quarterly	\$2,600,000
	Break even	1.7 tests / week

Over 90% EsoGuard Estimated Gross Margin at Volume

Source: Company reports.

Exhibit 9: Q2 2022 and Recent Business Highlights

Highlights from the second quarter and recent weeks include:

- LucidDx Labs Inc. ("LucidDx Labs"), Lucid's wholly owned CLIA-certified, CAP-accredited clinical laboratory is fully staffed and operational. The laboratory processed 850 commercial EsoGuard tests in the second quarter of 2022, which represents a 60% increase sequentially from the first quarter of 2022 and an over 300% increase annually from the second quarter of 2021. The proportion of tests performed at Lucid Test Centers increased and now represents about two-thirds of overall testing volume.
- Lucid continued its steady expansion of its sales team, particularly sales representatives who call on primary care physicians, and is progressing well toward reaching its year-end target of 39 such sales representatives and a total of 58 sales professionals. In concert with this expansion, we continue to hone our highly structured and data-driven standard operating procedures for sales processes and sales training.
- Lucid commenced stage two of its Lucid Test Center program launching new Lucid Test Centers in four new metropolitan areas: Orange County, California, the Dallas-Fort Worth, Texas metropolitan area, Palm Beach County, Florida, and Columbus, Ohio.
- LucidDx Labs' new revenue cycle management (RCM) partner is now in place and has commenced submitting claims to commercial payers. It also entered into four new participating provider agreements, including preferred provider organizations [Prime Health Services](#), [Three Rivers Provider Network](#), and [Galaxy Health Network](#) (the "PPOs"), as well as [Alivio Health](#), a specialized diagnostic laboratory network, covering millions of lives.
- Lucid and over a dozen partner entities, including key opinion leaders, National Cancer Institute-funded investigators, professional medical societies, patient and industry advocacy groups, participated in the now completed public comment periods following publication of a proposed "foundational" Local Coverage Decision by Medicare Administrative Contractor ("MAC") Palmetto GBA's MoIDX program as well as Noridian Healthcare Solutions, the MAC with jurisdiction over LucidDx Labs.
- [The American Gastroenterological Association](#) ("AGA") updated its clinical practice guideline entitled "[AGA Clinical Practice Update on New Technology and Innovation for Surveillance](#)," the first such update since 2011, following in the footsteps of the American College of Gastroenterology ("ACG"), which published a similar update in April. Both leading specialty associations now support Lucid's EsoCheck[®] Cell Collection Device and EsoGuard[®] Esophageal DNA Test as an acceptable alternative to endoscopy. Both guidelines expand the target population and addressable market opportunity for these products by no longer hedging on screening women. The AGA further expands the target population by now, for the first time, including asymptomatic patients in their recommendations who otherwise present with the applicable risk factors.

Source: Company reports.

Exhibit 10: Lucid Diagnostics Inc. Stock Price (since IPO in October 2021)



Source: <https://bigcharts.marketwatch.com/>

Exhibit 11: Consensus Expectations (as of August 15, 2022)

	Revenue (mil)			EPS	
	2022E	2023E		2022E	2023E
Q1 Mar	\$0.2A		Q1 Mar	\$(0.23)A	
Q2 Jun	\$0.6E		Q2 Jun	\$(0.33)E	
Q3 Sep	\$1.4E		Q3 Sep	\$(0.33)E	
Q4 Dec			Q4 Dec		
Total	\$4.8E	\$19.7E	Total	\$(1.34)E	\$(1.18)E

*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.

Source: Company report, Refinitiv, and Ascendant Capital Markets estimates

FINANCIAL MODEL

Lucid Diagnostics Inc.

Income Statement (\$ mils)	2019	Jun-20	Sep-20	2020	Mar-22	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023
Fiscal Year End: December 31	FY-A	Q1A & Q2A	Q3A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Total Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.5	0.2	0.0	0.4	3.6	4.2	4.0	4.2	4.4	5.4	18.0
Cost of Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.6	0.4	0.0	0.2	1.4	2.0	1.2	1.3	1.3	1.6	5.4
Gross Profit	0.0	0.0	0.0	0.0	0.0	0.0	0.1	(0.1)	(0.1)	(0.2)	0.0	0.2	2.2	2.2	2.8	2.9	3.1	3.8	12.6
Sales and marketing	0.0	0.3	0.3	1.3	0.7	1.0	1.0	3.3	5.9	3.3	3.9	4.0	4.0	15.2	4.0	4.0	4.0	4.0	16.0
General and administrative	1.0	0.8	0.5	1.5	1.2	3.1	3.4	6.3	14.0	5.7	7.3	7.0	7.0	27.0	7.0	7.0	7.0	7.0	28.0
Research and development	3.5	2.4	1.2	5.4	1.8	1.9	2.2	5.2	11.0	2.9	3.4	3.4	3.4	13.1	3.0	3.0	3.0	3.0	12.0
Restructuring and other	0.0			0.0					0.0					0.0					0.0
Total operating expenses	4.4	3.5	2.0	8.3	3.7	6.0	6.6	14.8	31.0	11.9	14.6	14.4	14.4	55.3	14.0	14.0	14.0	14.0	56.0
Operating income (loss)	(4.4)	(3.5)	(2.0)	(8.3)	(3.7)	(6.0)	(6.5)	(14.9)	(31.1)	(12.1)	(14.6)	(14.2)	(12.2)	(53.1)	(11.2)	(11.1)	(10.9)	(10.2)	(43.4)
Interest income (expense)	0.0			0.0		(0.1)	(0.4)	(0.1)	(0.7)			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other income (expense)	0.0			0.0					0.0	(0.2)		0.0	0.0	(0.2)	0.0	0.0	0.0	0.0	0.0
Income before income taxes	(4.4)	(3.5)	(2.0)	(8.3)	(3.7)	(6.2)	(7.0)	(15.0)	(31.7)	(12.3)	(14.6)	(14.2)	(12.2)	(53.3)	(11.2)	(11.1)	(10.9)	(10.2)	(43.4)
Income taxes	0.0			0.0					0.0					0.0					0.0
Net income (loss)	(4.4)	(3.5)	(2.0)	(8.3)	(3.7)	(6.2)	(7.0)	(15.0)	(31.7)	(12.3)	(14.6)	(14.2)	(12.2)	(53.3)	(11.2)	(11.1)	(10.9)	(10.2)	(43.4)
Nonrecurring/noncash adjustments		0.0	0.0		0.8	2.7	3.2	3.5	10.3	4.0	4.5	2.0	2.0	12.6	2.3	2.3	2.3	2.3	9.0
Net income (pro forma)	(4.4)	(3.5)	(2.0)	(8.3)	(2.8)	(3.4)	(3.7)	(11.4)	(21.4)	(8.2)	(10.1)	(12.2)	(10.2)	(40.7)	(9.0)	(8.8)	(8.7)	(8.0)	(34.4)
EBITDA		(3.5)	(2.0)	(8.3)	(3.6)	(6.0)	(6.5)	(11.2)	(27.4)	(12.2)	(13.9)	(10.0)	(8.1)	(44.2)	(7.0)	(6.9)	(6.7)	(6.0)	(26.7)
Shares, Basic	14.1	14.1	14.1	14.1	14.1	14.1	14.1	34.9	18.6	35.1	35.8	38.6	39.1	37.1	39.6	40.1	40.6	41.1	40.4
Shares, Diluted	14.1	14.1	14.1	14.1	14.1	14.1	14.1	34.9	18.6	35.1	35.8	38.6	39.1	37.1	39.6	40.1	40.6	41.1	40.4
EPS Basic (pro forma)	(\$0.31)	(\$0.25)	(\$0.14)	(\$0.59)	(\$0.20)	(\$0.24)	(\$0.26)	(\$0.33)	(\$1.15)	(\$0.23)	(\$0.28)	(\$0.32)	(\$0.26)	(\$1.10)	(\$0.23)	(\$0.22)	(\$0.21)	(\$0.19)	(\$0.85)
EPS Diluted (pro forma)	(\$0.31)	(\$0.25)	(\$0.14)	(\$0.59)	(\$0.20)	(\$0.24)	(\$0.26)	(\$0.33)	(\$1.15)	(\$0.23)	(\$0.28)	(\$0.32)	(\$0.26)	(\$1.10)	(\$0.23)	(\$0.22)	(\$0.21)	(\$0.19)	(\$0.85)
Margins																			
Gross margin							28%	-47%	-17%	-95%	#DIV/0!	55%	60%	53%	70%	70%	70%	70%	70%
Sales and marketing							489%	1087%	1190%	1756%	#DIV/0!	1000%	111%	363%	100%	95%	91%	74%	89%
General and administrative							1699%	2086%	2798%	3025%	#DIV/0!	1750%	194%	645%	175%	167%	159%	130%	156%
Research and development							1095%	1744%	2210%	1524%	#DIV/0!	850%	94%	313%	75%	71%	68%	56%	67%
Operating margin	NM	NM	NM	NM	NM	-3255%	-4964%	-6214%	-6401%	NM	-3545%	-340%	-1269%	-1269%	-280%	-263%	-248%	-189%	-241%
Tax rate, GAAP	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin	NM	NM	NM	NM	NM	-3478%	-4986%	-6346%	-6492%	NM	-3545%	-340%	-1273%	-1273%	-280%	-263%	-248%	-189%	-241%
Y/Y % change																			
Total Revenue												100%	1100%	738%	2016%	#DIV/0!	1000%	50%	330%
Gross margin												295%	-1635%	-2688%	-1656%	#DIV/0!	1300%	75%	473%
Sales and marketing				#DIV/0!	203%	192%	#DIV/0!	356%	381%	279%	309%	23%	155%	21%	3%	0%	0%	5%	
General and administrative				60%	295%	622%	#DIV/0!	813%	372%	134%	106%	12%	93%	22%	-4%	0%	0%	4%	
Research and development				57%	-22%	80%	#DIV/0!	103%	64%	84%	55%	-35%	19%	4%	-13%	-12%	-12%	-9%	
Operating income (loss)				87%	71%	222%	#DIV/0!	275%	231%	143%	118%	-18%	71%	-7%	-24%	-23%	-17%	-18%	
Net income (loss)				87%	75%	244%	#DIV/0!	283%	236%	137%	104%	-18%	68%	-9%	-24%	-23%	-17%	-19%	
EPS Diluted (pro forma)				87%	-2%	86%	#DIV/0!	96%	16%	16%	19%	-20%	-5%	-4%	-22%	-32%	-26%	-22%	

Source: Company reports and Ascendant Capital Markets estimates.

Lucid Diagnostics Inc.

Balance Sheet (\$ mils)	Dec-19	Dec-20	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23
Fiscal Year End: December 31	Q4A	Q4A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Assets													
Cash and cash equivalents	0.2	0.1	2.2	0.0	53.7	47.9	32.7	22.5	14.2	7.1	(0.0)	(7.5)	(13.7)
Short term investments								0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable				0.2	0.2	0.1		0.0	0.0	0.0	0.0	0.0	0.0
Deferred income taxes								0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other	0.2	1.3	1.8	2.3	3.4	4.3	3.2	3.2	3.2	3.2	3.2	3.2	3.2
Total current assets	0.4	1.4	4.1	2.5	57.3	52.3	35.9	25.7	17.4	10.3	3.2	(4.3)	(10.5)
Property and equipment, net					1.0	1.1	1.3	1.3	1.5	1.5	1.6	2.3	2.4
Intangibles, net						5.7	4.5	4.5	4.5	4.5	4.5	4.5	4.5
Deferred income tax								0.0	0.0	0.0	0.0	0.0	0.0
Other	0.6	0.8	0.8	0.8	0.7	2.9	3.8	3.8	3.8	3.8	3.8	3.8	3.8
Total assets	1.0	2.2	4.8	3.3	59.0	62.1	45.4	35.3	27.1	20.0	13.1	6.2	0.1
Liabilities and stockholders' equity													
Accounts payable	0.8	2.1	1.5	2.8	1.5	4.5	2.4	2.4	2.4	2.4	2.4	2.4	2.4
Accrued expenses	0.2	0.4	0.4	0.3	1.1	2.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
Deferred income tax								0.0	0.0	0.0	0.0	0.0	0.0
Other						5.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8
Due to PAVmed Inc.	5.3	13.3	22.9	24.3	1.7	1.8	2.4	2.4	2.4	2.4	2.4	2.4	2.4
Short term debt								0.0	0.0	0.0	0.0	0.0	0.0
Total current liabilities	6.3	15.7	24.8	27.4	4.3	14.1	7.9	7.9	7.9	7.9	7.9	7.9	7.9
Deferred income taxes								0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities								0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities						1.5	1.3	1.3	1.3	1.3	1.3	1.3	1.3
Long term debt								0.0	0.0	0.0	0.0	0.0	0.0
Total other liabilities	0.0	0.0	0.0	0.0	0.0	1.5	1.3	1.3	1.3	1.3	1.3	1.3	1.3
Preferred stock								0.0	0.0	0.0	0.0	0.0	0.0
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	8.2	12.3	16.4	20.5	24.5
Additional paid-in capital	0.2	0.3	3.7	6.5	96.6	100.6	105.0	105.0	105.0	105.0	105.0	105.0	105.0
Retained earnings	(5.5)	(13.8)	(23.6)	(30.6)	(41.9)	(54.2)	(68.8)	(83.0)	(95.2)	(106.4)	(117.5)	(128.4)	(138.6)
Accumulated other comprehensive income								0.0	0.0	0.0	0.0	0.0	0.0
Minority Interest								0.0	0.0	0.0	0.0	0.0	0.0
Total stockholders' equity	(5.3)	(13.5)	(19.9)	(24.1)	54.7	46.5	36.2	26.1	18.0	10.9	3.9	(2.9)	(9.1)
Total stockholders' equity and liabilities	1.0	2.2	4.8	3.3	59.0	62.1	45.4	35.3	27.1	20.0	13.1	6.2	0.1

Balance Sheet Drivers

	Dec-19	Dec-20	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23
	Q4A	Q4A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Book & Cash Value (per share)													
Book Value per Share (diluted)	(0.38)	(0.96)	(1.41)	(1.71)	1.57	1.32	1.01	0.68	0.46	0.27	0.10	(0.07)	(0.22)
Cash per Share (diluted)	0.01	0.01	0.16	0.00	1.54	1.36	0.91	0.58	0.36	0.18	(0.00)	(0.19)	(0.33)
Net cash per Share (diluted)	0.01	0.01	0.16	0.00	1.54	1.36	0.91	0.58	0.36	0.18	(0.00)	(0.19)	(0.33)

Source: Company reports and Ascendant Capital Markets estimates

Lucid Diagnostics Inc.

Cash Flow Statement (\$ mils)	2019	Jun-20	Sep-20	2020	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023
Fiscal Year End: December 31	FY-A	Q1A & Q2A	Q3A	FY-A	Q1A & Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Cash flow from operating activities																		
Net income	(4.4)	(3.5)	(2.0)	(8.3)	(9.8)	(7.0)	(11.3)	(28.1)	(12.3)	(14.6)	(14.2)	(12.2)	(53.3)	(11.2)	(11.1)	(10.9)	(10.2)	(43.4)
Depreciation				0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.1	0.9	0.1	0.1	0.1	0.1	0.4
Amortization				0.0				0.0					0.0					0.0
Debt related amortization expense				0.0				0.0					0.0					0.0
Stock comp	0.2	0.0	0.0	0.1	3.4	2.8	3.4	9.6	3.8	4.1	4.1	4.1	16.1	4.1	4.1	4.1	4.1	16.3
Deferred income taxes				0.0				0.0					0.0	0.0	0.0	0.0	0.0	0.0
Change in fair value of warrant liability				0.0				0.0	0.2	(0.2)			0.0					0.0
Writedowns and impairments				0.0				0.0					0.0					0.0
Other gains/losses				0.0				0.0					0.0					0.0
Other				0.0				0.0					0.0					0.0
Changes in operating assets and liabilities:																		
Accounts receivable				0.0		(0.2)		(0.2)	0.1	0.1			0.2					0.0
Prepaid expenses & other current assets	(0.9)	(0.5)	(0.4)	(1.1)	(0.5)	(0.4)	(1.1)	(2.1)	0.2	(0.9)	0.0	0.0	(0.7)	0.0	0.0	0.0	0.0	0.0
Other assets				0.0				0.0					0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	0.3	0.6	0.0	1.1	(0.5)	1.3	(1.4)	(0.7)	2.0	(1.0)	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0
Accrued expenses	0.0	0.1	0.2	0.2	(0.0)	0.2	0.6	0.7	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Due to PAVmed	2.5	0.9	0.6	2.4	1.7	1.0	0.4	3.1	0.1	(1.4)			(1.3)					0.0
Other liabilities				0.0	0.1	0.2	(0.4)	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash (used in) provided by	(2.4)	(2.4)	(1.6)	(5.6)	(5.6)	(2.2)	(9.9)	(17.7)	(5.8)	(13.3)	(10.0)	(8.1)	(37.1)	(7.0)	(6.9)	(6.7)	(6.0)	(26.7)
Cash flow from investing activities																		
Purchases of property and equipment				0.0	(0.0)	(0.0)	(0.8)	(0.9)	(0.1)	(0.2)	(0.1)	(0.2)	(0.8)	(0.1)	(0.2)	(0.8)	(0.1)	(1.3)
Purchases of short-term investments				0.0				0.0					0.0					0.0
Acquisitions				0.0				0.0		(2.2)			(2.2)					0.0
Other				0.0				0.0					0.0					0.0
Net cash used in investing activities	0.0	0.0	0.0	0.0	(0.0)	(0.0)	(0.8)	(0.9)	(0.1)	(2.4)	(0.1)	(0.2)	(3.0)	(0.1)	(0.2)	(0.8)	(0.1)	(1.3)
Cash flow from financing activities																		
Issuance of debt				0.0				0.0				0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of debt				0.0				0.0					0.0					0.0
Issuance of stock				0.0			64.3	64.3				0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds from stock option exercises		0.0		0.0				0.0	0.2	0.5			0.7					0.0
Other	2.5	2.9	1.1	5.6	7.7		(0.0)	7.7					0.0					0.0
Dividends and distributions				0.0				0.0					0.0					0.0
Cash provided by (used in) financing activities	2.5	2.9	1.1	5.6	7.7	0.0	64.3	72.1	0.2	0.5	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0
Effect of exchange rate on cash				0.0				0.0					0.0					0.0
Net increase (decrease) in cash	0.1	0.5	(0.5)	(0.0)	2.1	(2.2)	53.6	53.5	(5.7)	(15.2)	(10.1)	(8.3)	(39.4)	(7.2)	(7.1)	(7.5)	(6.2)	(28.0)
Beginning cash and equivalents	0.0	0.2	0.7	0.2	0.1	2.2	0.0	0.1	53.7	47.9	32.7	22.5	53.7	14.2	7.1	(0.0)	(7.5)	14.2
Ending cash and equivalents	0.2	0.7	0.2	0.1	2.2	0.0	53.7	53.7	47.9	32.7	22.5	14.2	14.2	7.1	(0.0)	(7.5)	(13.7)	(13.7)

Source: Company reports and Ascendant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

Lucid Diagnostics Inc.

- Ascendant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product/device candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize products, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech/medtech stocks, and changes in consumer or government priorities for healthcare.

Ascendant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Rating System

Prior to January 31, 2014, ASCM used the following rating system:

Strong Buy: We expect the stock to provide a total return of 30% or more within a 12-month period.

Buy: We expect the stock to provide a total return of between 10% and 30% within a 12-month period.

Neutral: We expect the stock to provide a total return of between minus 10% and plus 10% within a 12-month period.

Sell: We expect the stock to provide a total return of minus 10% or worse within a 12-month period.

Speculative Buy: This rating is reserved for companies we believe have tremendous potential, but whose stocks are illiquid or whose equity market capitalizations are very small, often in the definition of a nano cap (below \$50 million in market cap). In general, for stocks ranked in this category, we expect the stock to provide a total return of 50% or more within a 12-month period. However, because of the illiquid nature of the stock's trading and/or the nano cap nature of the investment, we caution that these investments may not be suitable for all parties.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of July 14, 2022)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	41	98%	15	37%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	42	100%	15	36%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer



The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.